Difference between revisions of "Rivaroxaban (Xarelto)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.<ref name="insert">[http://www.janssenmedicalinformation.com/assets/pdf/products/files/Xarelto/pi/ENC-010330-11.pdf Rivaroxaban (Xarelto) package insert]</ref><ref>[ | + | Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.<ref name="insert">[http://www.janssenmedicalinformation.com/assets/pdf/products/files/Xarelto/pi/ENC-010330-11.pdf Rivaroxaban (Xarelto) package insert]</ref><ref>[[Media:Rivaroxaban.pdf | Rivaroxaban (Xarelto) package insert (locally hosted backup)]]</ref><ref>[http://www.xarelto.com Xarelto manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 7: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.janssenmedicalinformation.com/assets/pdf/products/files/Xarelto/pi/ENC-010330-11.pdf | + | *[http://www.janssenmedicalinformation.com/assets/pdf/products/files/Xarelto/pi/ENC-010330-11.pdf Rivaroxaban (Xarelto) package insert]<ref name="insert"></ref> |
*[http://www.uptodate.com/contents/rivaroxaban-patient-drug-information Rivaroxaban (Xarelto) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rivaroxaban-patient-drug-information Rivaroxaban (Xarelto) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/rivaroxaban-patient-drug-information Rivaroxaban (Xarelto) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rivaroxaban-patient-drug-information Rivaroxaban (Xarelto) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 7/1/2011: | + | *7/1/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261839.htm FDA approved] "for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery." |
| + | *11/4/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm FDA approved] "to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | ||
| + | *11/2/2012: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm FDA approved] for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE." | ||
| + | |||
| + | ==Also known as== | ||
| + | BAY 59-7939 | ||
==References== | ==References== | ||
| Line 20: | Line 25: | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | + | [[Category:Anticoagulants]] | |
[[Category:Drugs FDA approved in 2011]] | [[Category:Drugs FDA approved in 2011]] | ||
Revision as of 08:18, 23 January 2015
General information
Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Rivaroxaban (Xarelto) package insert[1]
- Rivaroxaban (Xarelto) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/1/2011: FDA approved "for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery."
- 11/4/2011: FDA approved "to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation."
- 11/2/2012: FDA approved for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE."
Also known as
BAY 59-7939